Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
IMC-C103C is an immune mobilizing monoclonal T cell receptor against cancer (ImmTAC ®)
designed for the treatment of cancers positive for the tumor-associated antigen MAGE-A4. This
is a first-in-human trial designed to evaluate the safety and efficacy of IMC-C103C in adult
patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for
MAGE-A4.